JP2019506400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506400A5 JP2019506400A5 JP2018538190A JP2018538190A JP2019506400A5 JP 2019506400 A5 JP2019506400 A5 JP 2019506400A5 JP 2018538190 A JP2018538190 A JP 2018538190A JP 2018538190 A JP2018538190 A JP 2018538190A JP 2019506400 A5 JP2019506400 A5 JP 2019506400A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- agent
- antagonist
- activity
- blocks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 22
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 4
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000000139 costimulatory effect Effects 0.000 claims 3
- 230000001506 immunosuppresive effect Effects 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 2
- 230000037452 priming Effects 0.000 claims 2
- 238000009097 single-agent therapy Methods 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000003173 antianemic agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000003318 immunodepletion Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021196940A JP2022033899A (ja) | 2016-01-21 | 2021-12-03 | 免疫調節剤を併用するがんの治療 |
| JP2023047018A JP2023085370A (ja) | 2016-01-21 | 2023-03-23 | 免疫調節剤を併用するがんの治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281571P | 2016-01-21 | 2016-01-21 | |
| US62/281,571 | 2016-01-21 | ||
| US201662301981P | 2016-03-01 | 2016-03-01 | |
| US62/301,981 | 2016-03-01 | ||
| PCT/US2017/014375 WO2017127707A1 (en) | 2016-01-21 | 2017-01-20 | Treatment of cancer with combinations of immunoregulatory agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021196940A Division JP2022033899A (ja) | 2016-01-21 | 2021-12-03 | 免疫調節剤を併用するがんの治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506400A JP2019506400A (ja) | 2019-03-07 |
| JP2019506400A5 true JP2019506400A5 (enExample) | 2020-02-27 |
| JP7026047B2 JP7026047B2 (ja) | 2022-02-25 |
Family
ID=59360269
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538190A Active JP7026047B2 (ja) | 2016-01-21 | 2017-01-20 | 免疫調節剤を併用するがんの治療 |
| JP2021196940A Pending JP2022033899A (ja) | 2016-01-21 | 2021-12-03 | 免疫調節剤を併用するがんの治療 |
| JP2023047018A Pending JP2023085370A (ja) | 2016-01-21 | 2023-03-23 | 免疫調節剤を併用するがんの治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021196940A Pending JP2022033899A (ja) | 2016-01-21 | 2021-12-03 | 免疫調節剤を併用するがんの治療 |
| JP2023047018A Pending JP2023085370A (ja) | 2016-01-21 | 2023-03-23 | 免疫調節剤を併用するがんの治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20170210803A1 (enExample) |
| EP (2) | EP3405499A4 (enExample) |
| JP (3) | JP7026047B2 (enExample) |
| KR (1) | KR102833922B1 (enExample) |
| CN (1) | CN109071676A (enExample) |
| AU (2) | AU2017210224B2 (enExample) |
| CA (1) | CA3011429A1 (enExample) |
| SG (1) | SG11201806110QA (enExample) |
| WO (1) | WO2017127707A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10927173B2 (en) | 2016-01-11 | 2021-02-23 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-CD47 monoclonal antibodies |
| PL4177270T3 (pl) * | 2017-10-18 | 2024-11-18 | Forty Seven, Inc. | Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47 |
| CA3078430A1 (en) * | 2017-10-18 | 2019-04-25 | Forty Seven, Inc. | Treatment of ovarian cancer with anti-cd47 and anti-pd-l1 |
| EA202091339A1 (ru) | 2017-12-01 | 2020-10-21 | Сиэтл Дженетикс, Инк. | Антитела против cd47 и их применение для лечения онкологических заболеваний |
| EP3722312A4 (en) * | 2017-12-08 | 2021-07-21 | Hanx Biopharmaceutics, Inc | BISPECIFIC ANTI-PD-1 / CD47 ANTIBODIES AND ASSOCIATED APPLICATION |
| CN111699005A (zh) | 2018-02-12 | 2020-09-22 | 四十七公司 | 使用抗cd47抗体和抗cd20抗体的抗癌方案 |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| TW202028237A (zh) | 2018-09-27 | 2020-08-01 | 美商西建公司 | SIRPα結合蛋白及其使用方法 |
| WO2020072445A1 (en) * | 2018-10-01 | 2020-04-09 | Verastem, Inc. | Combination therapies |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN109517073A (zh) * | 2018-11-30 | 2019-03-26 | 北京泽勤生物医药有限公司 | 一种靶向治疗肿瘤的融合肽及其应用 |
| CA3122914A1 (en) * | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/sirp.alpha. molecule |
| WO2020163692A1 (en) * | 2019-02-08 | 2020-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway |
| EP3934658A4 (en) * | 2019-03-08 | 2023-03-29 | North Carolina State University | Bio-responsive antibody complexes for enhanced immunotherapy |
| US20220288118A1 (en) * | 2019-07-31 | 2022-09-15 | Forty Seven, Inc. | Depletion regimes for engineered t-cell or nk-cell therapy |
| CN115397853A (zh) | 2019-12-17 | 2022-11-25 | 辉瑞大药厂 | 对cd47、pd-l1具特异性的抗体及其用途 |
| CA3196402A1 (en) * | 2020-10-22 | 2022-04-28 | Dale L. Ludwig | Combination radioimmunotherapy and cd47 blockade in the treatment of cancer |
| EP4274853A4 (en) * | 2021-01-05 | 2024-12-04 | National Institute Of Biological Sciences, Beijing | BISPECIFIC ANTIBODY TARGETING GPC3 AND CD47 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| SI2477648T1 (sl) * | 2009-09-15 | 2022-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Sinergijska terapija proti CD47 za krvne rake |
| WO2011076781A1 (en) * | 2009-12-22 | 2011-06-30 | Novartis Ag | Tetravalent cd47-antibody constant region fusion protein for use in therapy |
| CA3138956A1 (en) | 2010-05-14 | 2011-11-17 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd47 |
| BR112014018331A8 (pt) * | 2012-01-25 | 2017-07-11 | Univ Texas | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação |
| PT2925782T (pt) * | 2012-12-03 | 2020-04-22 | Novimmune Sa | Anticorpos anti-cd47 e métodos de utilização destes |
| BR112015013431A2 (pt) * | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
| JP6426693B2 (ja) * | 2013-03-15 | 2018-11-21 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| WO2016023001A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| EP4186927B1 (en) * | 2015-10-21 | 2025-04-23 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| CN107459578B (zh) * | 2016-05-31 | 2021-11-26 | 泰州迈博太科药业有限公司 | 一种靶向cd47与pd-l1的双功能融合蛋白 |
-
2017
- 2017-01-20 KR KR1020187023116A patent/KR102833922B1/ko active Active
- 2017-01-20 CN CN201780018358.9A patent/CN109071676A/zh active Pending
- 2017-01-20 EP EP17742028.8A patent/EP3405499A4/en not_active Ceased
- 2017-01-20 EP EP22175627.3A patent/EP4070812A1/en active Pending
- 2017-01-20 SG SG11201806110QA patent/SG11201806110QA/en unknown
- 2017-01-20 US US15/411,623 patent/US20170210803A1/en not_active Abandoned
- 2017-01-20 WO PCT/US2017/014375 patent/WO2017127707A1/en not_active Ceased
- 2017-01-20 JP JP2018538190A patent/JP7026047B2/ja active Active
- 2017-01-20 AU AU2017210224A patent/AU2017210224B2/en active Active
- 2017-01-20 CA CA3011429A patent/CA3011429A1/en active Pending
-
2021
- 2021-04-08 US US17/225,668 patent/US20210230276A1/en active Pending
- 2021-12-03 JP JP2021196940A patent/JP2022033899A/ja active Pending
-
2023
- 2023-03-23 JP JP2023047018A patent/JP2023085370A/ja active Pending
-
2024
- 2024-05-02 AU AU2024202900A patent/AU2024202900A1/en active Pending
- 2024-11-06 US US18/939,377 patent/US20250066473A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506400A5 (enExample) | ||
| JP2023085370A5 (enExample) | ||
| Victora et al. | Germinal centers | |
| Mullins et al. | Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies | |
| US11376272B2 (en) | Methods of modulating immune activity | |
| RU2497542C2 (ru) | Нацеливание на антигенпрезентирующие клетки иммунонанотерапевтических средств | |
| Murray et al. | Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver | |
| CN104853776B (zh) | 免疫应答的增强 | |
| Sankar et al. | Early innate cell interactions with Mycobacterium tuberculosis in protection and pathology of tuberculosis | |
| KR20220131918A (ko) | 다이아실글리세롤 키나제 조절 화합물 | |
| Gadd et al. | Targeted activation of toll-like receptors: conjugation of a toll-like receptor 7 agonist to a monoclonal antibody maintains antigen binding and specificity | |
| Kawashima et al. | Priming and maintenance of adaptive immunity in the liver | |
| JP2012505245A5 (enExample) | ||
| Wang et al. | Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway | |
| JP2019503386A (ja) | 免疫療法を増強するためのヒストンデアセチラーゼ阻害剤の使用 | |
| Lin et al. | The effect of local non‐thermal plasma therapy on the cancer‐immunity cycle in a melanoma mouse model | |
| JP2020524149A5 (enExample) | ||
| Abusarah et al. | Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice | |
| Schulze et al. | A liposomal platform for delivery of a protein antigen to langerin-expressing cells | |
| JP2015523553A5 (enExample) | ||
| CN112638375A (zh) | 通过后细胞信号传导因子的调节来增加免疫活性 | |
| JP2022512161A (ja) | 免疫療法のための組成物及び方法 | |
| Xiong et al. | Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors | |
| Dhume et al. | Early programming and late‐acting checkpoints governing the development of CD 4 T‐cell memory | |
| JP6273290B2 (ja) | 疾患の処置のための同種異系のオートファゴソーム強化組成物 |